Formulation Development
EXECUTIVE INTERVIEW - TC BioPharm: Developing Platform Allogeneic Gamma-Delta T Cell Therapies for Cancer
Bryan Kobel, CEO of TC BioPharm, discusses his company’s upcoming plans, therapeutic clinical trials, and the biotech landscape.
FORMULATION DEVELOPMENT - Understanding CBD Formulation Versus Dosage Format
Gerry McNally, PhD, says there are many misconceptions when it comes to considering the best way or format to consume CBD and get the maximum benefit. Formulation scientists need to consider several factors when developing new formulations of nutraceutical ingredients, especially botanical ingredients and natural materials from various sources.
THERAPEUTIC FOCUS - Addressing the Unmet Need for Improved Treatments of Female Cancers
Martin Lehr, MA, explains how his company is advancing a pipeline of innovative products designed to address treatment resistance in breast, ovarian, and endometrial cancer, which, if approved, could provide patients with a much-needed new treatment options.
CLINICAL TRIALS - The Mission to Increase Diverse Clinical Trial Participation
Lauren Chazal, MBA, and Keidra Gaston, MBA, believe clinical trials are critical to advancing medical knowledge and new therapeutics; however, it is important that participants in clinical trials represent their entire communities and the potential recipients of new treatments.
PATIENTS-ON-A-CHIP - Why Artificial Intelligence Will Be the Tipping Point to Remove the Faulty Reliance on Animal Testing in Drug Discovery
Isaac Bentwich, MD, believes Advanced Bio-AI platforms that integrate artificial intelligence and machine learning with patients-on-a-chip, real-time nano-sensing, and stem cell genomic diversity technologies are the future of drug discovery and development.
Lonza Completes Expansion to Solid Form Services Facility at Oregon Site
The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules….
Ethicann & Catalent Sign Development & License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments
Catalent and Ethicann Pharmaceuticals Inc. recently announced the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s….
Global CDMO Adare Pharma Solutions Harmonizing Quality With Veeva Vault Quality Suite
Adare Pharma Solutions recently selected Veeva Vault Quality Suite to harmonize quality systems across the organization. By replacing legacy systems with modern connected applications, Adare can…
Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease
Pheno Therapeutics Limited. recently announced it has entered into an exclusive worldwide license agreement with UCB. The agreement grants Pheno Therapeutics access and rights to….
Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial
Emerald Health Pharmaceuticals Inc. recently received a positive safety review following a pre-specified interim analysis by the Safety Review Committee (SRC) of its Phase 2a…
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
BioXcel Therapeutics, Inc. recently announced promising top-line data from its Phase 2 trial of BXCL701, the company's investigational, oral innate immune activator, in combination with…
Sterling Pharma Solutions Completes Acquisition of API Manufacturing Facility in Ireland
Sterling Pharma Solutions recently announced the completion of its acquisition of an active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, from Novartis, in a…
Ajinomoto & Exelixis Enter License Agreement to Discover & Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Ajinomoto Co., Inc. recently announced a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of….
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for Novel Immunotherapeutic for Type 1 Diabetes
SAB Biotherapeutics recently announced the successful completion of an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic as a way to prevent and/or delay onset…
Absci First to Create & Validate De Novo Antibodies With Zero-Shot Generative AI
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic….
Atavistik Bio Announces Collaboration With Plex Research to Enrich the Informatics Capabilities of its AMPS Platform & Accelerate the Discovery of Novel Small Molecule Therapeutics
Atavistik Bio recently announced it has entered into a collaboration agreement with Plex Research, a company providing a novel artificial intelligence (AI)-powered drug discovery platform.…
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Vaccinex, Inc. recently announced its licensee, Surface Oncology dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s…
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients With Heart Failure With Preserved Ejection Fraction
Imbria Pharmaceuticals, Inc. recently announced the enrollment of the first patient in Part 2 of the IMPROVE-DiCE Phase 2 clinical trial of ninerafaxstat in patients…
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
Derm-Biome Pharmaceuticals, Inc. recently announced that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego (UCSD)…
Centogene & Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Centogene N.V. recently announced it has extended the Rostock International Parkinson's Disease (ROPAD) Study to recruit and genetically test additional patients over the next few…
